High FODMAP Diet with Metformin in PreDM
- Conditions
- PreDiabetesImpaired Glucose Tolerance
- Interventions
- Combination Product: Low FODMAP diet with metforminCombination Product: High FODMAP diet with metformin
- Registration Number
- NCT05628584
- Lead Sponsor
- Elaine Chow
- Brief Summary
This is a prospective, double blinded, randomised cross over feeding trial examine high or low FODMAP diet in combination with metformin on postprandial glucose responses and gastrointestinal tolerability and gut microbiota profiles.
The trial will compare high or low FODMAP diet, each of 10 days duration in combination with 5 days metformin, separated by a washout period of at least 2 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 26
- Age 18-70 years
- Body mass index 18 to 40 kg/m 2
- Prediabetes defined as impaired fasting PG 5.6-6.9 mmol/l and/or impaired glucose tolerance with 2-hour PG 7.8-11.1 mmol/l on 75g oral glucose tolerance test (OGTT) and/or HbA1c 5.7-6.4% at screening
- Currently pregnant, lactating, as demonstrated by a positive pregnancy test at screening or planning pregnancy
- Known current diabetes
- Current or previous use of glucose-lowering or weight loss drugs in 3 months prior to screening
- Concurrent participation in other weight loss or lifestyle intervention programmes
- Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
- Recent intake of prebiotic/probiotic or antibiotic, immunosuppressants (within 8 weeks of randomisation)
- Extensive skin changes/diseases that preclude wearing the FGM on normal skin at the proposed application sites (e.g., extensive psoriasis, recent burns or severe sunburn, extensive eczema, extensive scarring, extensive tattoos, dermatitis herpetiformis).
- Known uncontrolled thyrotoxicosis
- Known vitamin B deficiency
- Known irritable bowel syndrome or gastrointestinal disorders
- Estimated glomerular filtration rate (eGFR) <45 ml/min/1.73m2 at screening
- Current use of steroids
- Have a known allergy to medical-grade adhesives
- Known current or recent alcohol or drug abuse
- Hypersensitivity to metformin
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma within 3 months of randomisation
- Currently participating in another investigational study protocol where the testing or results may interfere with study compliance, diagnostic results, or data collection.
- An identified protected vulnerable patient (including but not limited to those in detention, or a prisoner).
- Participants who are on a vegetarian or vegan diet as their habitual diet at screening.
- Participants with clinically significant food allergy to components of the study diet
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description LOW FODMAP Low FODMAP diet with metformin - High FODMAP High FODMAP diet with metformin -
- Primary Outcome Measures
Name Time Method Differences in postprandial glycemia 10 days incremental area under curve on continuous glucose monitoring post meal
- Secondary Outcome Measures
Name Time Method Body weight 10 days Differences in body weight between arms
Glucose response to 75g oral glucose tolerance test 10 days fasting and postchallenge plasma glucose
Insulin response to 75g oral glucose tolerance test 10 days insulin levels
Change in alpha diversity of gut microbiota 10 days Changes in alpha diversity in gut microbiota
Change in beta diversity of gut microbiota 10 days Changes in beta diversity in gut microbiota
Gastrointestinal symptoms 10 days Measured on visual analogue scale 1-10 for each item, higher score indicates worse symptoms
Trial Locations
- Locations (1)
Prince of Wales Hospital
🇭🇰Sha Tin, Hong Kong